[ad_1]
The tests, carried out on 1,077 people, successfully developed the antibodies and white blood cells necessary to fight the virus.
This is of great hope to researchers, but it is not yet known whether it provides complete protection against the new coronavirus. The UK has already ordered 100 million units of the vaccine.
UK officials said on Monday they had signed a contract for an experimental vaccine against the new coronavirus that is being developed by the pharmaceutical giant Pfizer and others, 90 million. buy dose.
The British government said in a statement that it had secured the right to buy potential vaccines developed by Pfizer and BioNTech, as well as another experimental vaccine that Valneva is investigating.
The UK has previously signed a contract with AstraZeneca to provide € 100 million. Dosages of the vaccine against coronavirus infection COVID-19 are currently being tested at the University of Oxford. The company plans to publish more results on the progress of the investigation later Monday.
“Millions of people could be vaccinated against the coronavirus,” the British government said in a statement, referring to the three different vaccines in which it was decided to invest.
It is still unclear whether any of these vaccines will prove to be effective and safe, but Britain and other wealthy countries are already investing in these vaccines to ensure sufficient production capacity for any successful drug.
It usually takes more than a year to develop a vaccine, and dozens of them are currently being tested worldwide.
A British company announces an advance in the treatment of COVID-19
Treatment with a single spray can significantly reduce the number of deaths or the need for intensive care in patients infected with the new coronavir, according to preliminary results published Monday by a British biotechnology company.
Studies in a random sample of 100 patients diagnosed with COVID-19 coronavirus infection showed a 79% risk of developing severe disease in people treated with the aerosol protein interferon beta. less than in the placebo group alone.
Furthermore, patients treated with interferon were twice as likely to make a full recovery as controls.
The company that offered the therapy, called SNG001, said the preliminary results could indicate a “breakthrough” in the fight against the coronavirus pandemic.
“Everyone is satisfied with the results of a test published today that shows that SNG001 significantly reduced the number of patients hospitalized with COVID-19 who initially required oxygen and later [dirbtinis plaučių] ventilation, “said Richard Marsden, CEO of Synairgen.
Still, the results published on Monday had not yet been reviewed by the reviewers, and the patient group studied was relatively small.
If the test results are confirmed, this could lead to an advance in the treatment of hospitalized patients with COVID-19.
Radical change
Interferon beta is a natural protein in the body that regulates the immune system. Among other things, it is used to treat multiple sclerosis.
This protein is part of the body’s natural system to fight infection. The new coronavirus inhibits the production of interferon, so the body’s response to this infection is often inadequate.
Direct exposure to interferon in the lungs is intended to elicit a strong immune response to the virus in patients, including those whose immune system is already weakened by infection.
“These results confirm our belief that interferon beta … has great potential as an inhaled medication that can restore the pulmonary immune response,” said Tom Wilkinson, professor of respiratory diseases at the University of Southampton.
According to him, the study shows that SNG001 was an effective means of “improving protection, accelerating healing, and counteracting the effects of the SARS-CoV-2 virus.”
Naveed Sattar, professor of metabolic medicine at the University of Glasgow, said the new therapy could radically change the situation.
“With the little ones [tiriamųjų] the groups are less clear about the true level of benefit, as well as whether the positive effects are different for people with different risk characteristics, “said Sattar, who did not contribute to the study.
“Such work would require more research, but in any case, these results are very exciting,” he added.
Various therapies are currently offered to patients with COVID-19 treated in hospitals.
A team of researchers led by the University of Oxford in the United Kingdom last month said it had successfully reduced the risk of death in seriously ill patients with the widely available steroid dexamethasone.
Several countries have also urgently authorized the antiviral treatment of COVID-19 with remdesivir.
It is strictly prohibited to use the information published by DELFI on other websites, in the media or elsewhere, or to distribute our material in any way without consent, and if consent has been obtained, DELFI must be cited as the source.
[ad_2]
